Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928142 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
A Phase 2 study of Sjogren Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Active
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT06928142 is a Phase 2 study of Sjogren Disease that is active but no longer recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 83 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06928142, a Phase 2 study of Sjogren Disease, is active but no longer recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Sibeprenlimab
Study Locations (20)
Texas
- Allen Arthritis - Allen
- Tekton Research, LLC - Austin
- Advanced Rheumatology of Houston - Houston
- Accurate Clinical Research - Houston - Houston
- Accurate Clinical Management, LLC - Katy
- R & H Clinical Research - Katy
Florida
- Bay Area Arthritis and Osteoporosis - Brandon
- Clinical Research of West Florida Inc - Clearwater
- GNP Research - Florida - Cooper City
- Vantage Clinical Trials - Tampa - ClinEdge - PPDS - Tampa
California
- Medvin Clinical Research - Riverside - Riverside
- Medvin Clinical Research - Tujunga - Tujunga
Illinois
- OrthoIllinois, LTD - Rockford
- Arnold Arthritis and Rheumatology - Skokie
Louisiana
- Ochsner Clinic Foundation - Baton Rouge
Massachusetts
- Tufts University School of Dental Medicine - Boston
New Mexico
- Albuquerque Center for Rheumatology - Albuquerque
New York
- Bradenton Research Center Inc - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2027-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06928142
The ClinicalTrials.gov registry entry for NCT06928142 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06928142 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06928142 about?
NCT06928142 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's". This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
What is the current status of trial NCT06928142?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2025-04-23. Estimated completion is 2027-06-04.
What conditions does trial NCT06928142 study?
This clinical trial studies the following conditions: Sjogren Disease.
What interventions are being tested in trial NCT06928142?
The interventions under investigation include: Placebo (OTHER), Sibeprenlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06928142?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928142 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.